Kornimate/medical-research-clean huggingface dataset:
studying tumor tissue samples to learn more about dna changes and response in patients with breast cancer treated with bevacizumab on clinical trial ecog-2100

Conditions: Breast Cancer

Summary: rationale: studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. it may also help doctors understand how well patients respond to treatment. purpose: this laboratory study is examining tumor tissue samples from patients with breast cancer treated with bevacizumab on clinical trial ecog-2100 to learn more about dna changes and response in these patients.

objectives: primary * assess the effect of known variant polymorphisms (with functionally important associations) of the vascular endothelial growth factor (vegf) gene on outcome (time to progression) in patients with breast cancer treated with bevacizumab on clinical trial ecog-2100. secondary * assess the effect of known variant polymorphisms (with functionally important associations) of the vegf receptor-2 (kdr) gene on outcome (time to progression) in these patients. * assess the effect of known variant polymorphisms of these genes on efficacy (objective response rate and survival) in these patients. * assess the effect of known variant polymorphisms of these genes on toxicity outcome in these patients. * assess the effect of vegf polymorphisms on vegf expression by immunohistochemical staining (a known prognostic marker). * assess the effect of kdr polymorphisms on kdr expression by immunohistochemical staining. outline: this is a multicenter study. tissue and genomic dna samples from paraffin-embedded primary tumor are examined using standard polymerase chain reaction (pcr) restriction fragment-length polymorphisms, immunohistochemistry, allele-specific pcr, and/or taqman-based assays. vascular endothelial growth factor (vegf) and vegf receptor-2 (kdr) expression and polymorphisms are assessed. projected accrual: a total of 500 specimens will be accrued for this study.

Eligibility criteria:
disease characteristics: * histologically or cytologically confirmed adenocarcinoma of the breast * enrolled on clinical trial ecog-2100 and received treatment with bevacizumab * paraffin-embedded tumor samples available * hormone receptor status not specified patient characteristics: * female * menopausal status not specified prior concurrent therapy: * see disease characteristics

Keywords: recurrent breast cancer stage iv breast cancer
dpp-4 inhibition and tzd for dm prevention

Conditions: Prediabetic State

Summary: to determine whether treatment with the diabetes medication, januvia (sitagliptin), with or without another diabetes medicine, actos (pioglitazone), will improve insulin secretion and insulin response individuals with impaired glucose tolerance (igt), a form of prediabetes.


Eligibility criteria:
inclusion criteria: * impaired glucose tolerance (igt) by oral glucose tolerance test exclusion criteria: * history of diabetes mellitus * history of congestive heart failure * history of coronary artery disease or other macrovascular disease (stroke, peripheral vascular disease) * history of liver disease (alt or ast \>2.5 times the upper limit of normals) * history of renal disease (serum creatinine \>1.5 mg/dl) * history of severe osteoporosis (frequent fractures, failure on osteoporosis treatment) * current treatment with glucocorticoids * history of immune disorder, including hiv * women of child-bearing age who are pregnant, desire to become pregnant, are breastfeeding, or who refuse to take the recommended birth control measures

Keywords: prediabetic state
sleep apnea syndrome and vitamin d

Conditions: Obstructive Sleep Apnea-hypopnea Syndrome

Summary: obstructive sleep apnea/hypopnea syndrome (osahs) is a highly prevalent disorder with multiple comorbidities. osahs is characterized by repetitive episodes of airflow reduction (hypopnoea) or cessation (apnoea) due to upper airway collapse during sleep. its major risk factor is obesity. however, its pathogenesis is complex and multifactorial. reduced upper airway muscle tonus and/or unstable neuromuscular output seem to be involved in this collapsus. a normal vitamin d status is necessary for normal muscle function and neuromuscular output. as obesity is associated with a high rate of hypovitaminosis d, it appears of interest to evaluate the effect of vitamin d supplementation on osahs patients with vitamin d deficiency.

prospective, longitudinal, double bind, randomized study of the effect of vitamin d supplementation in osahs patients with hypovitaminosis d. after written informed consent, patients will be randomized to receive a single dose of oral vitamin d (400 000 ui) or placebo. subjects will undergo medical screening before randomisation into placebo or active group. follow-up measurements will be performed at the beginning (day 0) and after 32 days of vitamin d supplementation: clinical examination, biological check up and sleep parameter evaluation. patients will be instructed to stop using continuous positive airway pressure device for two nights before nocturnal sleep studies.

Eligibility criteria:
inclusion criteria: * moderate to severe obstructive sleep apnoea (ahi \> 15) * with or without continuous positive airway pressure for a minimum of six months * aged 30-75 years * vitamin d2d3 level \< 30 ng/ml exclusion criteria: * diseases or therapy known to interfere with phospho-calcium or vitamin d metabolism * patients with mixed sleep apnoea (central and obstructive) * patients with cpap use \< 4 hours per night * patients with maxillofacial or oro-pharyngeal diseases) * patients with chronic respiratory failure, hypercapnic patients * muscle diseases * alcohol intake \> 2 glasses per day * body mass index \> 40 kg/m2

Keywords: obstructive sleep apnea-hypopnea syndrome osahs vitamin d
tau imaging in young onset dementia

Conditions: Alzheimer's Disease, Early Onset; Logopenic Progressive Aphasia; Posterior Cortical Atrophy (PCA)

Summary: the central goal of this study is to determine and compare the similarities and differences in regional brain uptake of \[18f\]t807 in patients with typical alzheimer's disease (ad), posterior cortical atrophy (pca), and logopenic variant of primary progressive aphasia (lvppa). the investigators will correlate patterns of \[18f\]t807 binding with magnetic resonance imaging (mri)-based regional volumetric and cortical thickness measures. if cerebral spinal fluid (csf) samples are not available, patients may be asked to get an optional lumbar puncture (lp) for additional comparisons. the investigators will recruit 20 participants, 45-70 years old, with clinical evidence of young onset focal dementia.


Eligibility criteria:
inclusion criteria: 1. participants will be 45 - 70 years of age 2. mmse \> 10 at screening visit. 3. participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures. if the patient is unable to provide informed consent, the patient's legal representative may consent on behalf of the patient but the patient will be asked to confirm assent. 4. participants must be willing and able to comply with scheduled visits and imaging procedures. 5. a brain mri is required. if a brain mri has been performed within 6 months of enrollment to this study and of adequate quality that scan may be used for the study analysis, subjects who do not have a brain mri will undergo a brain mri either as a part of this study 6. participants must identify a study partner who is willing to accompany the patient to study visits exclusion criteria: 1. females who are pregnant or breast feeding at the time of screening scan will not be eligible for this study, urine or serum pregnancy test will be performed in women of child-bearing potential at the time of screening 2. inability to tolerate or contraindication to imaging procedures (pet/ct or mri) in the opinion of an investigator or treating physician 3. qtc \> 450 msec on screening ecg. 4. any medical or psychological conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study (e.g. moderate to large stroke or history of moderate or severe traumatic brain injury (tbi)).
virtual moud treatment- virtual poc toxicology

Conditions: Substance Use Disorder

Summary: care for substance use disorders (sud) such as medication treatment of opioid use disorder (moud) saves lives and is increasingly delivered virtually. currently, 60% of va outpatient addiction treatment occurs over video. however, toxicology testing, a major component of sud care, currently requires in-person visits. a process for virtual point-of-care toxicology testing is needed. this research will develop a virtual point-of-care toxicology testing process for va. this pilot trial will evaluate the feasibility, acceptability, and proximal effects of the process by evaluating provider and patient testing uptake, qualitative feedback, and health service use.

care for substance use disorders (sud) such as medication treatment of opioid use disorder (moud) saves lives and is increasingly delivered virtually. currently, 60% of va outpatient addiction treatment occurs over video. however, toxicology testing, a major component of moud care, currently requires in-person visits. a process for virtual point-of-care toxicology testing is needed. the objectives of this pilot project are to develop, feasibility test, and describe the proximal outcomes of a virtual point-of-care toxicology testing process for va patients in moud care. the process will be evaluated in a pilot trial among providers and patients at va connecticut (vact) and va central western massachusetts (vacwm). acceptability will be evaluated through patient and provider semi-structured interviews. overall feasibility will be determined using a priori benchmarks of utilization. these findings will be used to inform modifications of virtual toxicology testing procedures. mixed-methods will be used to develop and evaluate the testing process, which will use an oral-fluid test for common drugs of abuse. the test is fda approved for at home patient use. patients will self-administer the test during virtual sud visits and assess results with providers. in the pilot trial, a single-arm mixed-methods pilot trial will evaluate the process among patients and providers at two va facilities. feasibility will be evaluated by examining process uptake. acceptability will be evaluated through semi-structured interviews with patients and providers based on consolidated framework for implementation research (cfir) constructs. health service use will be evaluated by analyzing data on patient characteristics, test utilization, and treatment contacts extracted from the electronic medical record.

Eligibility criteria:
inclusion criteria: to participate va patients must * be recruited by their provider through a discussion about the project * be interested in participating after the discussion * have used va video-based care at least once * receive buprenorphine from a vact or vawcm provider (50% will have started buprenorphine within the last 3 months) * have the ability to receive mail from the va for the purposes of receiving oral fluid test kits) exclusion criteria: * veterans must not be receiving inpatient or day-program treatment

Keywords: substance use disorder opioid use disorder telemedicine toxicology
beijing protocol in patients receiving more than 5/10 hla-mismatched allo-hsct

Conditions: Hematologic Malignancy; Stem Cell Transplant Complications

Summary: the aim of the study is to evaluate the efficacy and safety of beijing protocol in malignant haematologic disease patients receiving more than 5/10 hla-mismatched allo-hsct.

allogeneic hematopoietic stem cell transplantation (allo-hsct) is a potentially curative procedure for patients with hematological malignancies.donor-recipient human leukocyte antigen (hla) compatibility plays a key role in successful allo-hsct as hla-matching has a direct impact on the risk of gvhd, non-relapse mortality (nrm), and survival. suitable, matched or haploidentical donors are not always available or accessible, even in the era of the international registries.therefore, there is a need for new strategies that could negate the barrier of hla-mismatching, allowing allo-hsct from traditionally prohibitive highly mismatched donors.the aim of the study is to evaluate the efficacy and safety of beijing protocol in malignant haematologic disease patients receiving more than 5/10 hla-mismatched allo-hsct.

Eligibility criteria:
inclusion criteria: * hematologic malignancy patients * patients eligible for the transplantation of allogeneic hematopoietic stem cells; * patients unavailable with hla matched donor or related haploidentical donor * voluntary participation in this study and signing the informed consent form. exclusion criteria: * patients with the severe infections; * pregnant or lactating women * patients who are not eligible for hematopoietic stem cell transplantation; * patients who are enrolled in other clinical trials within 1 month; * patients who may not be able to complete the study for other reasons, or may be considered by the investigator not suitable to participate in the study; * patients unable to properly understand or refusing to accept the informed consent form.

Keywords: allogenetic hematopoietic stem cell transplant hla locus hematologic malignancy
clinical predictors of short term outcomes of ablation of idiopathic monomorphic pvcs

Conditions: Arrythmia

Summary: clinical predictors of successful pvcs ablation

clinical predictors of short term outcomes of ablation of idiopathic monomorphic pre mature ventricular contractions

Eligibility criteria:
inclusion criteria: * patients with idiopathic monomorphic pvcs exclusion criteria: * patients with heart failure
ellipse intramedullary high tibial osteotomy nail study

Conditions: Osteoarthritis; Varus Malalignment

Summary: the purpose of this study is to collect outcomes data in patients implanted with the ellipse im hto nail system.


Eligibility criteria:
inclusion criteria: * patient implanted with the ellipse im hto nail system for osteoarthritis and varus malalignment of the knee * patient signs informed consent for the use of their personal private data. exclusion criteria: * patient is currently enrolled in another clinical trial for high tibial osteotomy.
peg-rhg-csf in patients with lymphoma receiving chemotherapy

Conditions: Lymphoma

Summary: the purpose of this study is to estimate the safety and efficacy of peg-rhg-csf in patients with lymphoma receiving chemotherapy.


Eligibility criteria:
inclusion criteria: * patients with age ≥ 18 years * diagnosis of lymphoma(hodgkin's lymphoma and non-hodgkin's lymphoma) patients * karnofsky performance status z70 * life expectancy of at least 8 months * normal white blood cell count and platelet count * written informed consent are acquired exclusion criteria: * uncontrolled infection * pregnancy * have accepted any other anti-tumor drug within 4 weeks before anticipated the study * other situations that investigators consider as contra-indication for this study
animal allergy in korean pet owners, pet-related industry workers, and laboratory animal reseachers

Conditions: Allergic Rhinitis; Allergic Conjunctivitis; Urticaria; Asthma

Summary: the investigators surveyed the prevalence of animal allergy and sensitization to animal allergen among participants in international symposium of korean association for laboratory science (laboratory animal researchers) and companion animal exhibition (pet owner and pet-related industry workers).

the investigators enrolled participants in international symposium of korean association for laboratory science (laboratory animal researchers) and pet animal exhibition (pet owner and pet-related industry workers) after informed consents. subjects were asked to response to questionnaires regarding their age, gender, comorbid allergic disease, family history of allergy, pet or laboratory animal, exposure time, allergic symptoms during exposure to animals. subjects underwent skin prick test with animal allergens and other inhalant allergens.

Eligibility criteria:
inclusion criteria: * participants in international symposium of korean association for laboratory science and companion animal exhibition from whom informed consents were obtained. exclusion criteria: * subjects who reject enrollment into this study.

Keywords: allergen allergy pet
pharmacotherapy and intensive treatment - 2

Conditions: Cocaine-Related Disorders; Substance-Related Disorders

Summary: the purpose of this study is to evaluate desipramine and carbamazepine in reducing cocaine craving; increase outpatient treatment capacity and evaluate their incidence of psychiatric disorders.


Eligibility criteria:
please contact site for information.

Keywords: cocaine dependence
dna analysis from isolated cardiomyocytes in the molecular diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia

Conditions: Arrhythmogenic Right Ventricular Dysplasia; Arrhythmogenic Right Ventricular Cardiomyopathy

Summary: the main objective of this study is to assess if it is possible, at the end of endocardial voltage mapping, to accurately collect intact cardiomyocytes and to isolate high quality dna allowing molecular testing of selected genes involved in arrhythmogenic right ventricular cardiomyopathy/dysplasia.

arrhythmogenic right ventricular cardiomyopathy/dysplasia is associated with mutations in genes encoding proteins from desmosomes and is characterized by a large expression variability. the classical molecular diagnosis from blood cells fails to identify mutations in around 30% of patients. probes used for endocardial voltage mapping allow to collect some cardiomyocytes which could be used for dna analysis. the aim of this project is to investigate if cardiomyocytes can efficiently be collected during endocardial voltage mapping in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. thirty patients suffering from arrhythmogenic right ventricular cardiomyopathy/dysplasia cardiac and needing endocardial voltage mapping for disease diagnosis and/or prognosis assessment will be included. the main outcome will be the percentage of patients in whom mapping will allow to collect intact cardiomyocytes from which high quality dna extraction will be achieved. other outcomes include the identification of new mutational mechanisms as somatic mosaicism in selected genes (pkp2, dscg2 dsp) and the feasibility of epigenetic analysis of these genes.

Eligibility criteria:
inclusion criteria: * patients needing endocardial voltage mapping in the context of arrhythmogenic right ventricular cardiomyopathy/dysplasia diagnosed using current criteria exclusion criteria: * patient under 18 years, pregnant women and patients under legal protection
study of the icg distribution in the margins of breast cancer after tumorectomy

Conditions: Breast Cancer

Summary: we will observe if icg fluorescence correlates with margins of breast tumours after iv injection of the contrast agent

in the operating room: icg 0.25 mg/kg will be given as an iv injection at least 20 minutes before the beginning of the operation. the surgeon will remove the tumour (and the axillary lymph nodes) as usual. optionally, peroperative "in vivo" imaging of the dissection of the tumour using the pde camera will be performed. in the laboratory of pathology: the "fresh" tumorectomy piece will be processed as usual, and the thick sections for the evaluation of the margins as well as the tissues samples from each margins will be imaged using the pde in comparison with the fluorescence in the mid part of the tumour and the fluorescent areas will be so delimited (and later analyzed in comparison with standards of known fluorescence intensity). after fixation, the tumoral tissues will be thereafter processed "as usual". if fluorescent foci are identified at the level of the axillary piece (in case of calnd), they will be dissected and processed as other lymph nodes. additionally, metastatic lymph nodes -if present- will also be controlled for their microscopic fluorescence or not. using the near-infrared fluorescence microscope, the slides corresponding to the macroscopically fluorescent structures will be analyzed.

Eligibility criteria:
inclusion criteria: * patients with histopathological diagnosis of mammary cancer who are candidate for tumorectomy, either with sln selective lymphadenectomy, or with complete axillary node dissection, * informed consent form signed. exclusion criteria: * diagnosis of mammary cancer established by "gross" biopsy, * age less than18 years old. * inability to give informed consent. * history of allergy or hypersensitivity against the investigational product (its active substance or ingredients), to iodine or to shellfish. * apparent hyperthyroidism, autonomous thyroid adenoma, unifocal, multifocal or disseminated autonomies of the thyroid gland. * documented coronary disease. * advanced renal impairment (creatinine \> 1,5mg/dl). * during the 2 weeks before the enrolment, concurrent medication which reduces or increases the extinction of icg (i.e. anticonvulsants, haloperidol and heparin). * pregnancy, breastfeeding

Keywords: margins tumorectomy
real-life use of cefazolin for the treatment of meticillin-susceptible staphylococcal infective endocarditis: comparison to a treatment cohort with penicillin m

Conditions: Infectious Disease; Endocarditis

Summary: retrospective, regional, multicenter study (including the annecy-genevois hospital center, the chambéry métropole savoie hospital center, and the grenoble university hospital center), comparing a cohort of patients treated with cefazolin with a cohort of patients treated with penicillin m

the use of cefazolin for the treatment of infective endocarditis caused by staphylococcus meti - s has become commonplace in france following the stockout of injectable penicillin m, the reference treatment, which occurred during 2016. there is currently no clinical data to prejudge the efficacy of cefazolin in the context of high inoculum, such as in the treatment of infective endocarditis. on the other hand, recent data have described a better tolerance profile for cefazolin than for penicillin m. the objective of this study is to compare the efficacy and safety of cefazolin with that of penicillin m in the management of methicillin-susceptible staphylococcal endocarditis, through the analysis of two retrospective cohorts.

Eligibility criteria:
inclusion criteria: * definite infective endocarditis according to duke criteria * documented sams or meticillin-sensitive scn * treated with cefazolin or penicillin m for at least 10 consecutive days * treatment initiated between 01/01/2014 and 12/31/2018 exclusion criteria: * patients under 18 years old * patients under 18 years old.

Keywords: cefazolin